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Reversible acetylation of histones and other proteins at speciﬁc lysine
residues by acetyltransferases is responsible for key cellular processes
such as chromatin organization and remodelling, gene-speciﬁc tran-
scription and signal transduction [1]. Themajor histone acetyltransferase
(HAT) families are conserved throughout evolution and comprise the
Gcn5-related N-acetyltransferases (GNATs) Gcn5 and PCAF; the MYST
(forMOZ, Ybf2/Sas3, Sas2 and Tip60)-related HATs; p300/CREB-binding
protein (CBP) HATs, including Rtt109, a distant homolog of p300 from
Saccharomyces cerevisiae [2,3]; general transcription factor HATs such as
TBP-associated factor-1 (TAF1); and the nuclear hormone-related HATs
SRC1 and ACTR [4]. HATs operatewithinmultiprotein complexes such as
the SAGA, ADA, SLIK, ATAC, TFTC and STAGA complexes for the GNATs;
the NuA3, NuA4, MOZ and SAS-1 complexes for the MYSTs; and
complexes with the histone chaperones Asf1 (or Vps75) for Rtt109
[4,5]. The same enzyme is often found in more than one complex andmany of them also catalyze the acetylation of non-histone substrates,
leading to changes in activity or stability of the targeted proteins, thereby
affecting a variety of cellular processes [6].
Loss-of-function or gain-of-function alterations in these pleiotro-
pic effectors can have severe consequences, including malignant
transformation [6–8] and defects in embryonic differentiation [9].
Structural studies on Gcn5/pCAF substrates, such as histone H3 and
p53, have shown that recognition of acetylation sites can be strongly
inﬂuenced by associationwith accessory proteins [10]. Themajority of
chromatin modiﬁers show additional conserved domains devoted to
the interaction with modiﬁed marks, such as the acetyl lysine-reading
bromodomain [11]. Nucleosome modiﬁcation and protein acetylation
are thus part of interconnected, but as yet incompletely understood
networks. In this scenario, compounds capable of modulating the
acetylation state of histone and non-histone proteins are of great
interest for both experimental biology and therapeutic purposes [12].
Histone deacetylase (HDAC) inhibitors have been extensively inves-
tigated as new potential drugs for the treatment of various diseases
and many of them are already in clinical trials [13,14]. By comparison,
only a few HAT inhibitors have been described so far. They include
natural products such as the p300/PCAF inhibitors anacardic acid
[15,16] and garcinol [17], and the p300 inhibitor curcumin [18], as
well as synthetic compounds such as peptide-CoA-based PCAF
inhibitors, many isothiazolones acting on PCAF and the Gcn5 inhibitor
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product derivatives [19,20].
One of the latter compounds, a quinolic analogue of anacardic acid
named MC1626 (Fig. 1, panel a), was previously shown to interfere
with histone acetylation and Gcn5-dependent transcriptional activa-
tion in yeast [21], despite its inability to inhibit yeast Gcn5 in vitro
[22]. This seemingly contrasting behaviour may reﬂect a preferential
action of MC1626 on Gcn5-related multiprotein complex components
rather than Gcn5 itself and/or the parallel inhibition of a different HAT
complex as well as the variety of cellular processes that are
interconnected with histone acetylation.
Here we report the results of a chemogenomic proﬁling analysis
aimed to delineate the cellular processes targeted by MC1626, by
examining the ﬁtness of a genome-wide collection of yeast deletion
mutants exposed to sublethal concentrations of this histone hypoa-
cetylating compound.Fig. 1. Histone hypoacetylating activity ofMC1626. a) Structure ofMC1626. b) Concentration-d
of Ac-H3 andAc-H4were normalizedwith respect to Ada2p (average±SDof three independen
ofMC1626(1 mM,YPDmedium)on the acetylationof speciﬁc histoneH3 lysine residues (K9,K1
of the actin (ACT1) gene. Representative data obtained from a ChIP analysis conducted on u
panacetylated Ac-H3 antibodies for immunoprecipitation; also shown is the linear ampliﬁcatio
control (No). The bar plot, derived fromquantiﬁcationof PCR ampliﬁcation signals, shows the am
cells (grey bars) relative to untreated cells (white bars; 100%); data are the average of two inde2. Results and discussion
2.1. Chemogenomic analysis
Serial dilution assays (not shown) were initially carried out with
the wild-type (WT) parent strain in order to determine sublethal
MC1626 concentrations (i.e., concentrations allowing for ~90%
growth compared to an untreated control after 48 h) in different
culture media. These were 1.5 mM and 0.85 mM in YPD and SCD
media, respectively (see ‘Materials and methods’ for details). As
shown in Fig. 1 (panel b), MC1626 inhibited histone, especially H3,
acetylation, in a dose-dependentmanner. However, as revealed by the
experiment in Fig. 1 panel c, in which acetyl lysine residue-speciﬁc
antibodies were utilized, MC1626 inhibits the acetylation of different
H3 tail lysine residues with little (if any) selectivity. As further shown
by the chromatin immunoprecipitation (ChIP) experiment reportedependent effect ofMC1626 onH3 andH4 (pan)acetylation (in YPDmedium). The amounts
t experiments) and are expressed relative to untreated (−) cells (100%). c) Inhibitory effect
4,K18,K23andK27as indicated). d)Effect ofMC1626onAc-H3 levels in thecoding region
ntreated cells (−MC1626) and on cells treated with 1 mM MC1626 (+MC1626) using
n of different amounts of input DNA (Total) along with a “no primary antibody” negative
ounts ofACT1 amplicon immunoprecipitatedby anti-Ac-H3 antibodies inMC1626-treated
pendent experiments that differed by no more than 15% of the mean.
Table 1
Biological processes associated with genes causing MC1626 sensitivity when deleteda.
GO functional categories MC1626-sensitive
mutant gene deletions
frequency (%)
Genome
frequency (%)
P-value
Cellular component
organization
44.3 24.5 4.15E−13
Organelle organization 31.9 15.8 3.29E−11
Chromosome organization 12.3 5.5 4.50E−04
Vacuole organization 3.6 0.6 6.70E−04
Membrane organization 9.0 3.4 7.70E−04
Cellular cation homeostasis 6.6 1.4 1.00E−06
Vacuolar acidiﬁcation 5.1 0.3 6.84E−15
Macromolecule
Biosynthetic process
47.0 29.1 1.20E−09
Establishment of
localization in cell
21.4 9.2 3.40E−09
Intracellular transport 19.3 8.6 2.17E−07
Vacuolar transport 8.7 1.7 2.01E−10
Vesicle-mediated transport 13.6 5.0 5.15E−07
Protein targeting to vacuole 4.2 0.9 4.10E−04
Golgi vesicle transport 7.5 2.5 6.50E−04
Regulation of gene
expression
28.6 14.4 3.78E−09
Regulation of transcription,
DNA-dependent
18.4 8.6 5.05E−06
Transcription from RNA
polymerase II promoter
13.6 5.1 8.78E−07
Lipid metabolic process 10.8 3.9 1.53E−05
Regulation of
transposition,
RNA-mediated
3.3 0.5 8.60E−04
aBiological process Gene Ontology (GO) terms were identiﬁed and evaluated for statistical
signiﬁcance (P-valueb0.001)with theGOTermFinder program (http://www.yeastgenome.
org/cgi-bin/GO/goTermFinder.pl). “Parent terms” are shown in bold, “child terms” in italics.
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within the coding region of the constitutively expressed actin (ACT1)
gene.
A screening of the yeast mutant collection treated with MC1626
was then conducted in triplicate in YPD medium (see ‘Materials and
methods’ for details). Mutant strains that proved to be MC1626-
sensitive in at least two replicates were pinned in duplicate onto 384-
well plates (along with 120 MC1626-insensitive mutants as negative
controls), transferred to SCD-agar plates, and re-checked for MC1626
(0.85 mM) sensitivity. Thirty-nine unconﬁrmed mutants were thus
discarded, and the remaining 332 MC1626-sensitive strains were
further veriﬁed by serial dilution assays and classiﬁed according to
their levels of sensitivity (“high”, HS; “medium”, MS; and “low”, LS;
see Supplementary Table S1 for a list of all the MC1626-sensitive
mutants, and Fig. 2 for representative examples of MC1626 sensitivity
phenotypes). Fifteen MC1626-sensitive mutant strains are deleted in
genes coding for uncharacterized ORFs (see Supplementary Table S1).
Human orthologs were identiﬁed for about 60% of the genes causing
MC1626 sensitivity when deleted, 30 of which correspond to genes
previously found to be involved in human diseases (Supplementary
Table S2).
As revealed by the Gene Ontology (GO) analysis reported in
Table 1, various cellular processes are engaged in the modulation of
MC1626 sensitivity. Among the most signiﬁcant there are four
functional categories bearing upon transcription-dependent DNA
transactions and “chromosome organization” (see below); “macro-
molecule biosynthesis”, which includes the speciﬁc paralogs of
various translation components (e.g., seven mitochondrial and 17
cytoplasmic ribosomal proteins); plus a number of detoxiﬁcation-
related processes accounting for approximately one-third of the
MC1626-sensitive mutants. About 70% of the latter mutants are
deleted in genes involved in vacuole biogenesis and functionality (see
Supplementary Table S1). Also included in this group are various
genes whose products are involved in speciﬁc lipid metabolism
pathways (e.g., ergosterol and sphingolipid biosynthesis), defects in
which can alter membrane permeability directly or by negatively
inﬂuencing the activity of membrane proteins. Collectively, these
mutants identify a subset of organelles and pathways – primarily the
vacuole, but also the endosome, the Golgi and associated transport
vesicles – that appear to be involved in MC1626 detoxiﬁcation. This is
further supported by the data in Table 2, which indicate such
compartments as major subcellular sites of gene products whose
deletion causes MC1626 sensitivity.Fig. 2. Representative mutant strains displaying different degrees of MC1626 sensitivity. The
48 h at 30 °C in the absence (left panel) or in the presence (right panel) of 0.85 mM MC162
dilution assays (10-fold dilution increments are shown from left to right in each panel, startin
at the ﬁrst, second, third (or higher) dilution were classiﬁed as having a “high” (HS), “med2.2. Mutants deleted in chromatin modiﬁcation and transcription-
related genes are hypersensitive to MC1626
As mentioned earlier, a highly populated group of mutants,
accounting for nearly 30% of the MC1626-sensitive strains, is deleted
in genes involved in processes such as “regulation of gene expression”,
“transcription from RNA polymerase II promoter”, “regulation of
transposition” and “chromosome organization” (Table 1; but see also
Supplementary Table S1). Growthdefects associatedwith the lack of the
corresponding gene products, which preferentially localize to the
nuclear periphery (Table 2), may be related to the histone acetylationwild-type BY4742 strain (WT) and the indicated deletionmutant strains were grown for
6 in synthetic complete medium (SCD). MC1626 sensitivity was determined by serial
g from an OD600 of 1.0). Mutant strains exhibiting a reduction in colony-forming ability
ium” (MS) or “low” (LS) sensitivity to MC1626.
Table 2
Subcellular localization of gene products that cause MC1626 sensitivity when deleteda.
MIPS subcellular localization category P-value
Vacuole 1.60E−08 (*)
Vacuolar membrane 5.58E−07 (*)
Endosome 1.22E−04 (*)
ER membrane 5.88E−03
Nuclear pore 7.50E−03
ER 9.63E−03
Mitochondrial matrix 2.72E−02
Golgi 5.08E−02 (*)
Golgi-ER transport vesicles 5.35E−02 (*)
Actin cytoskeleton 6.08E−02
Other transport vesicles 9.80E−02 (*)
Nuclear envelope 9.82E−02
aProteinswere classiﬁed in eachMunich InformationCenter for Protein Sequences (MIPS)
subcellular localization using the FunSpecprogram(http://www.funspec.med.utoronto.ca/);
cellular compartments potentially involved in drug detoxiﬁcation are marked with an
asterisk (*).
275R. Ruotolo et al. / Genomics 96 (2010) 272–280defects caused byMC1626 [21,23]. Especially noteworthy in this regard,
are genes encoding various components of chromatin remodelling/
modiﬁcation complexes such as SWI/SNF and SAGA, transcription
factors (e.g., Swi4, Swi6 and Mot3), enzymes involved in the structural
organization and metabolism of nucleic acids (e.g., Top1 and Est3), theFig. 3. Chemical-genetic synthetic proﬁling of HAT-related deletion mutants treated with
rtt109Δ, hpa2Δ, and hat1Δ) (a) and HAT chaperones (asf1Δ and vps72Δ) (b) mutant strains w
Fig. 2 legend for details).histone H2A variant HTZ1, and several nuclear pore proteins (e.g.,
Nup84 and Nup133).
Mutants deleted in the histone acetyltransferases Gcn5 and Rtt109
also displayed chemical-genetic synthetic sickness when exposed to
MC1626 (Fig. 3, panel a). Gcn5 and Rtt109 deletants were the only
HAT mutants that turned out to be MC1626 sensitive. Importantly,
Gcn5 and Rtt109 are both primarily directed to histone H3, a
preferential target of MC1626, and share at least three lysine residues
(H3-K9, H3-K23 and H3-K27 [24–26]), whose acetylation is inhibited
by MC1626 in vivo (see Fig. 1, panel d). Of note, H3-K9 acetylation in
yeast is exclusively performed by Gcn5 and Rtt109, and acetylation by
the latter HAT requires the histone chaperones Asf1 and Vps75 [26],
which also cause MC1626 sensitivity when deleted (Fig. 3, panel b).
Gcn5 is required for the activation of genes involved in amino acid
biosynthesis, respiration, cell cycle progression, chromosome segre-
gation and spindle dynamics, and other SWI/SNF-dependent path-
ways [27]. Rtt109, instead, regulates Ty transposition [28], another
process that is negatively inﬂuenced by MC1626 (see Table 1), and
promotes genome stability and resistance to DNA-damaging agents
[29] (see below). The latter effect strictly depends on acetylation of
K56 in the globular domain of histone H3, an exclusive task of Rtt109,
together with the histone chaperone Asf1, in yeast [26,30,31]. As
shown in Fig. 4, treatment of WT cells with MC1626 caused a
concentration-dependent reduction of this particular histoneMC1626. Incremental dilutions of control WT cells and of the indicated HAT (gcn5Δ,
ere grown for 48 h at 30 °C in SCD medium supplemented with 0.85 mMMC1626 (see
Fig. 4. Inhibition of H3-K56 acetylation by MC1626. a) Protein extracts from wild-type
cells grown in the absence (−) or in the presence of MC1626 at the indicated
concentrations (in YPD medium) were assayed for H3-K56 acetylation. b) The amounts
of Ac-H3-K56 in extracts fromMC1626-treated cells, normalized with respect to Ada2p
(average ±SD of three independent experiments), are expressed relative to untreated
(−) cells (100%).
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be a target of MC1626. Of note, K56 acetylation has recently been
shown to be functionally coupled with the acetylation of H3 tail lysine
residues [25], some of which (e.g. K18), are selectively acetylated by
Gcn5 [26]. This particular histone acetylation pathway has been
shown to take place on free histone H3 and to be crucial for de novo
nucleosome assembly, assisted by the Asf1 chaperone, both during
DNA replication and repair. The fact that both Rtt109 and Gcn5 work
in parallel to promote this “acetylation cascade” ﬁts with our
observation that these HATs (and their associated multiprotein
complex components) are the only ones that cause MC1626
sensitivity when deleted.
A unifying scheme linking about one-third of “chromatin modiﬁ-
cation/transcription” mutants to these two MC1626-sensitive HAT
deletants (gcn5Δ and rtt109Δ) was obtained by interactome analysis
(see Supplementary Fig. S1). As outlined in Fig. 5, 36 out of 80
MC1626-sensitive mutants belonging to this group functionallyFig. 5. Venn diagram representation of the interactions between chromatin modiﬁcation/t
Rtt109 and Gcn5 HATs. Physical and genetic interactions were retrieved from BioGRID (httinteract with either Gcn5 (28%, P-valueb4.3×10−5), or Rtt109
(28%, P-valueb1.4×10−4). This indicates that not only the lack of
Rtt109 or Gcn5, but also deletion of various components functionally
related to these two HATs can lead to chemical-genetic synthetic
lethality (or sickness) in MC1626-treated cells.
2.3. MC1626 sensitivity associated with mitochondrial and
cytoskeletal mutations
Mutations in speciﬁc mitochondrion- and cytoskeleton-related
genes also cause MC1626 sensitivity (Table 2). About 40% of the
MC1626-sensitive mutants are deleted in mitochondrial genes and in
nuclear or cytoplasmic genes involved in mitochondrion biogenesis
and functionality (see also Supplementary Table S1). Mutations in
these genes, which lead to respiration defects (e.g. isa1Δ, cox19Δ) as
well as to mitochondrial genome instability or loss (e.g., aim21Δ,
aim26Δ, abf2Δ), cause synthetic lethality (or sickness) when
combined with MC1626 (see Fig. 6 for representative examples).
Indeed, even the viability of the wild-type strain cultured onMC1626-
supplemented medium containing ethanol as the sole source of
carbon appeared to be severely compromised (Fig. 6).
Interestingly, among these MC1626-sensitive strains there are
various mutants deleted in genes involved in glycolysis (e.g., gcr2Δ,
pfk1Δ, and pfk2Δ), a metabolic pathway that is essential for the
anaerobic utilization of glucose under conditions of impaired
respiration.
On a related note, it is known that mutations affecting cytoskel-
eton organization and dynamics can impair mitochondrion transmis-
sion [32–34] as well mitochondrial membrane potential, leading to
ROS overproduction and apoptosis [35], along with cell cycle defects,
altered chromosomal segregation and abnormal bud shape [36].
Conversely, Gcn5 deletion alters spindle dynamics and makes cells
hypersensitive to microtubule destabilizing drugs [37]. In keeping
with these observations, we found that several MC1626-sensitive
mutant strains are deleted in genes coding for microﬁlament (e.g.
cap2Δ, sac6Δ) and microtubule (e.g. gim5Δ, spc72Δ) related compo-
nents — an indication that MC1626 treatment and Gcn5 deletion can
impair cytoskeleton organization. In fact, co-treatment with sublethal
doses of MC1626 and benomyl, a drug that disrupts microtubules but
also affects actin distribution, dramatically worsened the growth
phenotype of MC1626-sensitive cytoskeleton mutants and also
reduced viability of the wild-type strain (Fig. 7). Defects in
microtubule organization also cause the so called “mitotic catastro-
phe”, a type of cell death characterized by mitotic blockage, spindle
disorganization, loss of chromosome segregation and multinucleate
cell accumulation [38,39]. Interestingly, cellular phenotypes closely
resembling those associated with this particular type of cell death
have previously been reported for about 30% of the MC1626-sensitive
mutant strains identiﬁed in our screen (http://www.yeastgenome.
org/), including gcn5Δ [37].ranscription-related gene products whose deletion causes MC1626 sensitivity and the
p://www.thebiogrid.org/; see also Supplementary Fig. S1).
Fig. 6. MC1626 sensitivity of strains bearing speciﬁc mitochondrial mutations. Serial dilutions of WT and rho0 (i.e., without mtDNA) cells, and of mutant strains with an elevated
frequency of mitochondrial genome loss (aim26Δ) or lacking speciﬁc mitochondrial enzymes (oar1Δ, cox19Δ) were spotted on glucose (SCD) or ethanol (SCE) minimal complete
medium with or without 0.85 mM MC1626 (see ‘Materials and methods’ and Fig. 2 legend for details).
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To highlight potential commonalities between MC1626 and other
xenobiotics, we compared our data with those obtained from previous
chemogenomic proﬁling studies conducted under conditions similar to
those utilized for the present analysis [40–43]. As shown in Fig. 8, the
DNA-damaging agents bleomycin (20% of MC1626-sensitive mutants),
methyl methane sulfonate (8%) and camptothecin (6%) displayed the
closest similarity to MC1626. Bleomycin andmethyl methane sulfonate
damage DNA directly [44,45], while camptothecin causes DNA lesions
indirectly via inhibition of topoisomerase I [46]. The latter is encoded by
a single-copy gene whose deletion makes cells sensitive to MC1626.
The involvement of Rtt109 in genome stability [29], along with the fact
that several mutants displaying multixenobiotic sensitivity are deleted
in genes coding for nuclear or mitochondrial DNA repair components
(e.g., fyv6Δ,msh1Δ,met18Δ, and rad52Δ) or proteins that are otherwise
involved in chromatin modiﬁcation and transcription, suggests that
MC1626 interferes with DNA repair indirectly. It is known, in fact, that
by inﬂuencing the access of various nuclear proteins to DNA, chromatin
state, and especially histone acetylation, can modulate different DNA
transactions besides transcription (e.g., DNA repair, replication and
transposition). An altered acetylation state caused by the lack of certain
HATs or by treatment with a hypoacetylating agent such as MC1626
would thus lead to increased levels of unrepaired DNA and DNA
damage checkpoint activation [47]. For example, impaired H3-K56
acetylation as in Rtt109 or Asf1 deletants – both of which are sensitive
to various genotoxic agents [29,48] – is known to severely interfere
with DNA damage repair during S-phase [30], and the same likelyFig. 7. Synergistic effect of MC1626 and benomyl on the viability of particular cytoskeleton
actin-related protein involved in chromatin remodelling (arp8Δ), microtubule (alf1Δ, gim5
sublethal concentrations of benomyl (5 μg/ml), MC1626 (0.85 mM), or both drugs as indicapplies to WT cells treated with MC1626. Also notable in this context is
the increased sensitivity to genotoxic agents previously reported for
mutants lacking Gcn5 and the SWI/SNF chromatin remodelling
complex component Snf5 [49], both of which cause MC1626 sensitivity
when deleted. In keeping with a joint role of these two HATs in
nucleosome assembly following DNA repair, it has been reported
recently that gcn5Δrtt109Δ double mutants as well gcn5Δ mutants
bearing a non-acetylatable Arg residue at position 56 of histone H3
(K56R) are both much more sensitive to DNA-damaging agents than
the corresponding single mutants [25]. Furthermore, deletion of
speciﬁc Gcn5 multiprotein complex components (e.g. Ada1 and Spt7),
whose disruption in a rtt109Δ background has been shown to
phenocopy gcn5Δrtt109Δ [25], also conferred MC1626-sensitivity.
3. Conclusions
As revealed by this study, the quinoline derivativeMC1626 negatively
affects yeast cell growth by interferingwith seemingly distinct pathways.
Most of these pathways bear upon transcription-dependent DNA
transactions and chromosome organization, and are centred on histone
acetylation, while others are only indirectly linked to these processes.
HistoneH3 acetylation emerged as the preferential target ofMC1626, and
the histone acetyltransferases Gcn5 andRtt109,which function inparallel
yet distinct pathways in yeast, were the only ones that caused chemical-
genetic synthetic sickness with MC1626 when mutated. Particularly
revealing, in this regard, were the inhibitory activity of MC1626 against
Rtt109-speciﬁc (H3-K56) as well as Gcn5-speciﬁc (H3-K18) acetylations
[26,30,31], and the drug-sensitivity caused by deletion of genes coding formutant strains. Increasing dilutions of WT cells and of mutant strains lacking a nuclear
Δ) or actin (sac6Δ) cytoskeleton components were spotted on SCD plates containing
ated.
Fig. 8. Comparison with other cytotoxic agents. Hierarchical clustering of MC1626-sensitive gene deletions with the mutant sensitivity proﬁles of other xenobiotics, obtained with
the haploid deletionmutant collection using experimental conditions similar to those utilized in this study [40–43]. The x-axis corresponds to the gene deletions and the y-axis to the
various xenobiotics: camptothecin (Campt); methyl methane sulfonate (MMS); bleomycin (Bleo); menadione (Men); hydrogen peroxide (H2O2); cumene hydroperoxide (CHP);
linoleic acid 13-hydroperoxide (LoaOOH); diamide (Diam). Mutant strains displaying an enhanced sensitivity or no phenotype are shown in green and black, respectively. Mutants
were hierarchically clustered with EPCLUST (average linkage, uncentered correlation; http://www.bioinf.ebc.ee/EP/EP/EPCLUST/); only mutant strains co-sensitive to at least two
xenobiotics were taken into account for analysis.
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complex components [25,30,31]. Additionally, the MC1626 sensitivity
displayed by several DNA repair mutants is in accordance with the
recently documented functional association between Rtt109 and Gcn5 in
supporting histone H3 acetylation during post-repair (and replication-
coupled) nucleosome assembly, thus promoting DNA integrity [25,29].
This further strengthens the existence of a close link between chromatin
state, DNA stability and DNA repair propensity. A similar association
between histone modiﬁcation and DNA integrity has been reported
recently in human cells, where K56 acetylation is performed by hGCN5
and p300, a HAT structurally related to Rtt109 [3]. Interestingly,
acetylation of human H3-K56 is strongly inhibited by curcumin, a p300
inhibitor [18,50]witha chemogenomicproﬁle resembling thatofMC1626
(data not shown). Gaining more insight on the mode of action and the
actual targets of MC1626 will likely require the use of selected
heterozygous deletion mutants (e.g., strains deleted in Rtt109 and Gcn5
multiprotein complex components and other MC1626-sensitive mutants
identiﬁed in this work) and the exploitation of compound-induced
haploinsufﬁciency phenotypes.
Most MC1626-sensitivity causing mutations not directly linked to
histone acetylation negatively affect mitochondrion functionality. Even
the wild-type strain becomes respiratory-deﬁcient when treated with
MC1626. These non-nuclear effects of a hypoacetylating compound
such as MC1626 are likely explained by the extensive cross-talk
between the nucleus and the mitochondrion. It has been reported, for
example, that substitution of histoneH3K9, K14, K18, K23 andK27with
glycine residues abolishes growth on ethanol (a respiratory carbon
source) [51], while ASF1 deletion severely affects mitochondrial proton
pump functionality [52]. On a related note, it has been shown that
acetylcarnitine formed in themitochondria is transferred to the nucleus
where it serves as a source of acetyl groups for histone acetylation [53].
Similar indirect mechanisms likely underlie the MC1626 sensitivity
of particular subsets of cytoskeleton mutants, some of which displayed
synergic hypersensitivity to MC1626 and benomyl. These include the
actin regulators Cap1, Cap6, Sac6 and Arc18, the dynactin complex
components Arp1 and Jnm1 required for proper nuclear migration and
spindle partitioning, the spindle checkpoint protein Bub1, and three
components of the multiprotein tubulin chaperone GIM (Gim4, Gim5
and Pac10). Of note, ﬁve of the previously mentioned gene products
interactwithRtt109 and/orAsf1 and, albeit to a lower extent,withGcn5
multiprotein complex components (Supplementary Fig. S2).
Although the pharmacological potential of MC1626 is limited by its
submillimolar ED-50 dose, it is being used as a lead compound for the
developmentofmore effectivederivatives [23]. However, as highlighted
by the present work, MC1626 lends itself as a hypoacetylating
compound that can aid further dissection of histone H3-related
processes and their multifaceted interconnections.4. Materials and methods
4.1. Yeast strains and media
The collection of haploid MATα deletion mutant strains was
obtained from Open Biosystems and converted to a 384-well plate
format by manual multipinning [54]. Cells were grown on yeast
extract-peptone-dextrose (YPD) medium and on glucose (SCD) or
ethanol (SCE) synthetic complete media, unsupplemented or supple-
mented with MC1626 as indicated.
4.2. Protein extraction and immunoblot analysis
Protein extracts, prepared as described in [55], were fractionated on
15% polyacrylamide-SDS gels and transferred to nylon membranes
(Hybond, GE Healthcare). Following membrane blocking and incubation
with different primary antibodies (diluted as speciﬁed by the manufac-
turers; see below), immune-reactive polypeptides were visualized by a
chemiluminescent detection system (ECL; GE Healthcare) as per
manufacturer's instructions; the transcriptional coactivator Ada2 served
as an internal reference. Primary antibodies utilized for immunoblot
analysis were from the following sources: anti-pan-acetylated H3, anti-
pan-acetylated H4, anti-H3-AcK9, anti-H3-AcK14, anti-H3-AcK23, anti-
H3-AcK27 and anti-H3-AcK56 (Upstate Biotechnology); anti-H3-AcK18
(Abcam); anti-Ada2p (Santa Cruz).
4.3. Chromatin Immunoprecipitation
ChIP analysis was performed as described previously [37]. The
oligonucleotide primers ACT1R (5′-ACACTTCATGATGGAGTTGTA-3′)
and ACT1F2 (5′-GCTGAAAGAGAAATTGTCCG-3′) were used to amplify
a selected (245 bp) region of the actin (ACT1) ORF with Taq
polymerase (New England Biolabs). Input and immunoprecipitated
template concentrations were titrated into the linear range.
4.4. Screening of the deletion mutant collection
A total of 4688 haploid deletion mutant strains, not including 90
strains that failed quality control and 48 slow-growth strains previously
shown to exhibit a high false-positive rate (http://www-sequence.
stanford.edu/group/yeast_deletion_project/ deletions3.html), were
utilized for the analysis. Serial dilution spot assays (starting from
cultures pre-grown in minimal medium to an OD600 of 1.0 and diluted
up to 10,000 fold in ten-fold increments before spotting; see next
section)were initially carriedoutwith theparentWT(BY4742) strain to
determine MC1626 concentrations allowing for about 90% of control
(i.e., without MC1626) growth after 48 h at 30 °C. Optimal MC1626
279R. Ruotolo et al. / Genomics 96 (2010) 272–280concentrations of 1.5 mM in YPD and 0.85 mM in SCD medium were
thus determined andutilized for the screening,whichwas conducted by
manual multipinning, followed by visual inspection and digital image
recording of colony growth as described previously [54].
4.5. Validation assays
Strains that were scored as sensitive in the primary screeningwere
individually veriﬁed by serial dilution spot assays. To this end, mutant
strains of interest were grown in SCD medium for 48h at 30 °C, the
OD600 of individual cultures was then determined with a microplate
reader, adjusted with SCD medium to an OD600 value of 1.0, and
serially diluted in ten-fold increments. Aliquots (4 μl) of each dilution
were then spotted onto agar plates in the presence or absence of
MC1626 and growth was examined after incubation at 30 °C for 2 to
3 days. Mutant strains exhibiting a reduction in growth at the ﬁrst,
second, third (or fourth) dilution were classiﬁed as having a “high”,
“medium”, or “low”MC1626 sensitivity (HS, MS, and LS, respectively;
see Fig. 2 for representative phenotypes). Two strains identiﬁed as
MC1626-sensitive (ycl007cΔ and ypl205cΔ) correspond to “dubious”
ORFs (http://www.yeastgenome.org/index. shtml) overlapping the
bona ﬁde ORFs VMA9 and HRR25, none of which is present in the
mutant collection; both strains were replacedwith the latter ORFs and
included in the ﬁnal dataset (Supplementary Table S1).
4.6. Data analysis
Homology searches were carried out with BLASTP, the Princeton
Protein Orthology Database (P-POD; http://www.ortholog.princeton.
edu/help.html) and the Online Mendelian Inheritance in Man database
(OMIM; http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim). Infor-
mation on gene function and on previously determined mutant
phenotypes was retrieved from the Saccharomyces Genome Database
(SGD; http://www.yeastgenome.org/). Biological processes associated
with MC1626-sensitivity modulating genes were identiﬁed and evalu-
ated for statistical signiﬁcance (P-value) with the Gene Ontology (GO)
Term Finder program (http://www.geneontology.org/). Interactions
between the subset of MC1626-sensitivity modulating genes involved
in processes such as “regulation of gene expression”, “transcription from
RNA polymerase II promoter”, “regulation of transposition” and
“chromosome organization”, and the Rtt109 and Gcn5 HATs were
identiﬁed computationally using the Network Visualization System
Osprey (http://www.biodata.mshri.on.ca/osprey) and visualized as
speciﬁed in the BioGRID database (version 2.035 release; http://www.
thebiogrid.org/) and in the Osprey reference manual. P-values for
interactome analysis were determined by a one-tailed test, based on
the hypergeometric distribution as described previously [54].
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ygeno.2010.08.005.
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